Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Buys $256,050.00 in Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Jay R. Luly acquired 45,000 shares of the stock in a transaction that occurred on Wednesday, February 12th. The stock was purchased at an average price of $5.69 per share, with a total value of $256,050.00. Following the transaction, the chief executive officer now owns 846,638 shares in the company, valued at $4,817,370.22. This represents a 5.61 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Enanta Pharmaceuticals Trading Down 4.8 %

ENTA stock opened at $7.14 on Friday. The stock has a 50-day moving average price of $5.74 and a two-hundred day moving average price of $9.50. The stock has a market cap of $152.32 million, a PE ratio of -1.30 and a beta of 0.54. Enanta Pharmaceuticals, Inc. has a 1 year low of $4.71 and a 1 year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. On average, analysts forecast that Enanta Pharmaceuticals, Inc. will post -5.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Robert W. Baird lowered their price objective on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, November 26th. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday. JMP Securities restated a “market outperform” rating and issued a $21.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday. Finally, StockNews.com cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Two analysts have rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Enanta Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $17.25.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Krensavage Asset Management LLC grew its holdings in shares of Enanta Pharmaceuticals by 19.7% in the 3rd quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock valued at $15,520,000 after acquiring an additional 246,736 shares in the last quarter. RA Capital Management L.P. bought a new position in shares of Enanta Pharmaceuticals in the 4th quarter valued at about $5,968,000. Marshall Wace LLP grew its holdings in shares of Enanta Pharmaceuticals by 9.3% in the 4th quarter. Marshall Wace LLP now owns 930,087 shares of the biotechnology company’s stock valued at $5,348,000 after acquiring an additional 79,197 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Enanta Pharmaceuticals by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock valued at $4,946,000 after acquiring an additional 14,575 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Enanta Pharmaceuticals by 6.4% in the 3rd quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock valued at $4,662,000 after acquiring an additional 27,147 shares in the last quarter. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.